Esperion Theraptc ESPR

$3.18 -0.01 (-0.31%)

Valuation

Market cap
819,464,000
Revenue TTM
$403,140,000
Net income TTM
$-22,680,000
PE ratio
0.00
Forward PE
—
Profit margin
-5.63%
Debt to equity
-0.50

Trading

Volume
59,090,402
Avg volume
17,213,020
Day's range
$3.18 – $3.19
Shares out
257,693,000
Stochastic %K
75%
Beta
1.07
Analysts
Hold
Price target
$2.97

Price

Company profile

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in a...

Show more

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. As of July 13, 2026, Esperion Therapeutics, Inc. was taken private.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
734 887 3903
Website
https://www.esperion.com
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, United States

Latest news

Stocktwits

Highbred Oct 23, 11:46 PM
$ESPR the playbook here seems obvious now, given how it all played out. The biggest player Archimed, knew what it was seeing and doing all along. Us retail simply didnt hold the keys, and couldnt access the full potential for profit. We here knew this is a blockbuster drug...and deserved a much higher public valuation. The big money on the other hand, also saw the same....and carved out a road to assume even greater profits, all for theirselves, over a longer time period. While us retail awaited a massive and fair buyout price (one time profit) the big money, awaited circumstances which would payout massive profits, annualy, repeatedly over more than a decade. This is the real game....as rigged as it appears from our perspective....it was well played by the real players.
0 replies
Progressive_Trading Oct 23, 10:40 PM
$ESPR — Mr. Riddle has gone quiet again. Looks like the red has taken away his usual bravado. I owned you, along with your little brother @Spaceequiped! Now, go mow the yard, my dear sons!
0 replies
MastermindTrader Oct 23, 10:13 PM
Put FMFC on your watchlist for next week. 💎 FMFC has barely 450 watchers on Stocktwits and large social media accounts are covering it. Webull data showing that FMFC has only 492k shares outstanding and 242k shares float. $ESPR good swing
0 replies
__LucidDreamer__ Oct 23, 5:32 PM
$CATX Target: $0.70 Why? Because all speculative shitty biotech stocks seem destined for that level. Good news: if it hits $.070 then you sell at $2 for a massive win when the heavily share-comped execs are “aligned with shareholders”. $RADX $ESPR
0 replies
Enjoyycall Oct 22, 10:14 AM
$ESPR What was his name…I’m happy for the BUYOUT!
0 replies
Enjoyycall Oct 22, 10:10 AM
$ESPR Still winning 🏅. Who buys on small windows. What was his name…I can’t remember. ESPR owned y’all. 😂😆😱✈️
0 replies
refinedindividual Oct 21, 11:14 PM
$ESPR Was a long time holder. my basis was $2.31. life has been good post buyout. I owned 110,000 shares. what i made post buyout would be equivalent to $6.47 now. Dont know why I am here except I always believed ESPR was worth $11. oh well
2 replies
Progressive_Trading Oct 21, 9:31 PM
$ESPR — My dear son @Spaceequiped, tell your little friend @Enjoyycall that acting all tough and then blocking people is cowardly behavior. Everyone is entitled to act stupid, but he seems to be abusing that privilege. I owned you both! I’m watching you... Mow the yard!
0 replies